Article

Gynecomastia and premature - Thelarche: A guide for practitioners

Division of Pediatric Endocrinology, Department of Pediatrics, Miller School of Medicine, University of Miami, Miami, FL, USA.
Pediatrics in Review (Impact Factor: 0.82). 10/2007; 28(9):e57-68. DOI: 10.1542/pir.28-9-e57
Source: PubMed

ABSTRACT Gynecomastia in males and premature thelarche in females are common conditions in the pediatric population. Although gynecomastia and premature thelarche represent benign physiologic conditions in most cases, it is important to recognize and treat those patients who may have underlying pathologic conditions. Clues to underlying disease include age of onset, extent and progression, presence of accompanying signs of pubertal development, and use of drugs. If clues to underlying conditions are identified, referral to a specialist is warranted.

1 Follower
 · 
135 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Gynecomastia is often benign, but it can be the sign of serious endocrine disease and the source of significant embarrassment and psychological stress. Understanding its pathogenesis is crucial to distinguish a normal developmental variant from pathological causes. There is a growing list of potential causes of gynecomastia. Rare and unique case reports continue to supplement the literature to augment our understanding of this common physical finding. However, the exact basis for the pathogenesis of gynecomastia remains unknown. There appears to be a local imbalance between estrogen stimulation and the inhibitory action of androgens on breast tissue proliferation. Gynecomastia in a prepubertal boy is rare and should prompt an immediate evaluation for possible endocrine disorder. Pubertal gynecomastia, on the contrary, is common and usually physiological, with sympathetic reassurance and watchful waiting the mainstays of treatment. There is some evidence that early pharmacological intervention with antiestrogens may diminish persistent pubertal gynecomastia, but treatment with an aromatase inhibitor has not been shown to be more effective than placebo. Treatment of gynecomastia is geared toward its specific cause. Currently, there are insufficient data to recommend medical therapy in children with idiopathic gynecomastia.
    Current opinion in pediatrics 09/2008; 20(4):465-70. DOI:10.1097/MOP.0b013e328305e415 · 2.74 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: While gynecomastia is common in adolescents, male breast cancer in the pediatric population is exceedingly rare. Occasional reports describe malignant and pre-malignant lesions in mastectomy specimens for gynecomastia in young adults. We present a 16-year-old male with unilateral gynecomastia discovered to have ductal carcinoma in situ (DCIS), treated by mastectomy with 4 year follow-up.
    Pediatric Surgery International 10/2008; 24(11):1251-3. DOI:10.1007/s00383-008-2246-1 · 1.06 Impact Factor
  • Source
    01/2009;
Show more